<SEC-DOCUMENT>0001493152-23-020081.txt : 20230605
<SEC-HEADER>0001493152-23-020081.hdr.sgml : 20230605
<ACCEPTANCE-DATETIME>20230605080532
ACCESSION NUMBER:		0001493152-23-020081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230605
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230605
DATE AS OF CHANGE:		20230605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		23991278

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:DARE="http://darebioscience.com/20230605">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_DARE_darebioscience.com_20230605 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20230605_20230605 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001401914 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityRegistrantName_Dare Bioscience, Inc. -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityCentralIndexKey">0001401914</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityRegistrantName">Dare Bioscience, Inc.</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="dare-20230605.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-06-05to2023-06-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-05</xbrli:startDate>
        <xbrli:endDate>2023-06-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20230605__20230605_zcXHi7rpb7Zh"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>of
the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_90D_edei--DocumentPeriodEndDate_c20230605__20230605_znoYWsrWVOU2"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 5, 2023</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 18pt"><b>DAR&#201;
BIOSCIENCE, INC.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20230605__20230605_zgRN31jDVqi2"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20230605__20230605_z2ZIHczgE902"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityFileNumber">001-36395</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20230605__20230605_z8RuEJGsmM4e"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityTaxIdentificationNumber">20-4139823</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230605__20230605_zUeBNl1k2Ht8"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityAddressAddressLine1">3655
Nobel Drive</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20230605__20230605_zk6T7yD2Bszb"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityAddressAddressLine2">Suite 260</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20230605__20230605_zq2CK2v0noGb"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityAddressCityOrTown">San
Diego</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20230605__20230605_za61eBnKnypa"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20230605__20230605_zOCJwaDJ6Oma"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:EntityAddressPostalZipCode">92122</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Address
of Principal Executive Offices and Zip Code)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_90D_edei--CityAreaCode_c20230605__20230605_zH1GP34Yefw7"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:CityAreaCode">(858)</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20230605__20230605_z8KDcQEgXeBk"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:LocalPhoneNumber">926-7655</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span>Not
Applicable</span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Former
name or former address, if changed since last report.)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<i>see</i> General Instruction A.2. below):</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; width: 0.25in"><span id="xdx_905_edei--WrittenCommunications_c20230605__20230605_z7e199uANwU8"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span id="xdx_90C_edei--SolicitingMaterial_c20230605__20230605_z53I5npsn59l"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span id="xdx_902_edei--PreCommencementTenderOffer_c20230605__20230605_zwKGkCYGa9bl"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20230605__20230605_z8EHoiMkJsO2"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; width: 38%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; width: 18%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; width: 40%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_906_edei--Security12bTitle_c20230605__20230605_zflCOvTKe1L1"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:Security12bTitle">Common
    stock</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_905_edei--TradingSymbol_c20230605__20230605_zI7RUmMqePQc"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" name="dei:TradingSymbol">DARE</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90B_edei--SecurityExchangeName_c20230605__20230605_zSDF5WaOJxPb"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 27pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_907_edei--EntityEmergingGrowthCompany_c20230605__20230605_zvRqHOi4Lxcb"><ix:nonNumeric contextRef="From2023-06-05to2023-06-05" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Item
    7.01</b></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Regulation
    FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On
June 5, 2023, Dar&#233; Bioscience, Inc. (Dar&#233;), issued a press release reporting topline results from the clinical trial discussed
in Item 8.01 below. A copy of the press release is furnished as Exhibit 99.1 to this report.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
information under this Item 7.01 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933 or
the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in
any such filing, except as shall be expressly set forth by specific reference in such a filing.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Item
    8.01</b></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Other
    Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>Topline
results from exploratory Phase 2b RESPOND clinical trial of Sildenafil Cream, 3.6%</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">On
June 5, 2023, Dar&#233; announced topline results from its exploratory Phase 2b RESPOND clinical trial of Sildenafil Cream, 3.6% (Sildenafil
Cream) in patients with female sexual arousal disorder (FSAD). The exploratory Phase 2b RESPOND study was a multi-center, double-blind,
randomized, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream in premenopausal patients with FSAD. The
study was a first of its kind Phase 2b clinical study that includes patient reported outcome (PRO) instruments to screen eligible women
with FSAD and included two co-primary endpoints, a secondary endpoint, and a number of exploratory endpoints to measure, among other
things, improvement in localized genital sensations of arousal, reduction in the distress that women experience with FSAD and satisfactory
sexual events.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">There
are no treatments approved by the U.S. Food and Drug Administration (FDA) for FSAD and thus there are no efficacy endpoints that have
been previously validated in a Phase 3 pivotal study for potential treatments for FSAD. The exploratory Phase 2b RESPOND study also served
as a validation study of exploratory endpoints that could be candidate endpoints in a Phase 3 study of Sildenafil Cream. The FDA requested
that any PROs for use in the assessment of efficacy in a Phase 3 study be adequately validated. Part of that validation of the PROs
includes exit interviews performed as part of the exploratory Phase 2b RESPOND study to better understand qualitatively what constitutes
a meaningful change to the subjects. These qualitative assessments of meaningful change were utilized to determine which endpoints achieved
meaningful improvement in the Sildenafil Cream group. Additional psychometric analyses using the exploratory Phase 2b RESPOND
study dataset is planned to further refine and validate the measures to inform the most appropriate endpoints for use in a Phase
3 pivotal study of Sildenafil Cream.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
exploratory Phase 2b RESPOND study began with 99 subjects in the Sildenafil Cream intent to treat population and 93 subjects in the placebo
intent to treat population, with 70 subjects in the Sildenafil Cream intent to treat population and 60 subjects in the placebo intent
to treat population completing the study, and therefore was underpowered to assess statistical significance, although certain
endpoints achieved statistical significance. During the study, participants used Sildenafil Cream and a placebo cream in their home setting
and documented their experience using PRO instruments. The study evaluated Sildenafil Cream compared to placebo cream over 12 weeks of
dosing following both a non-drug and placebo run-in period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&#233;
intends to review the data with the FDA, including discussing the data from assessments as early as the 4- and 8-week mark after randomization,
and to continue the development of Sildenafil Cream, including advancing Sildenafil Cream into a Phase 3 pivotal study for the treatment
of FSAD. Following clinical development, Dar&#233; intends to leverage the existing safety and efficacy data on the active ingredient
in Sildenafil Cream to utilize the FDA&#8217;s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream in the U.S.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Summary
of Topline Data</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A
co-primary endpoint of the Phase 2b RESPOND study was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by
change from baseline to the end of the study in the Arousal-Sensation Domain of the 28-item Sexual Function Questionnaire (SFQ28). The
endpoint did not achieve statistical significance. However, the change at the end of the study in the group treated with Sildenafil Cream
was consistent with how women reported meaningful improvement in an exit interview at the end of the study.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
other co-primary endpoint was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to
the end of the study in the score for feeling concerned by difficulties with sexual arousal. The change was assessed using the previously
validated Female Sexual Distress Scale &#8211; Desire, Arousal and Orgasm (FSDS-DAO) Survey. This assessment did not differentiate Sildenafil
Cream from placebo.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
secondary endpoint was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to the end
of the study in the number of satisfactory sexual events based on the subjects&#8217; response to a question answered and recorded via
electronic diary within 24 hours after each sexual event. The endpoint was selected because it can serve as a primary endpoint in a Phase
3 study based on the FDA draft 2016 guidance document for female sexual dysfunction. When measured at the 4- and 8-week mark after randomization,
subjects treated with Sildenafil Cream had a higher proportion of satisfying sexual events during the prior month (68.6% and 74.1% at
the 4- and 8-week mark, respectively) compared to those treated with placebo (47.9% and 67.9% at the 4- and 8-week mark, respectively)
(week 4 P value = 0.04).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
exploratory endpoints (selected based on the content validity study previously conducted by SST and Dar&#233;) included endpoints related
to genital arousal, genital blood flow, lubrication, orgasm, concerns about difficulties with sexual arousal, and other assessments including
questions regarding satisfying sexual events. The exploratory endpoints were assessed at multiple periods over the course of the study
via electronic diary.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">An
                                            exploratory endpoint regarding concerns about difficulties with sexual arousal differentiated
                                            Sildenafil Cream versus placebo. Specifically, when asked about their overall impression
                                            of change regarding their concerns about difficulties with sexual arousal, women treated
                                            with Sildenafil Cream were more likely to report an overall improvement. Based on responses
                                            to the question at the 4-, 8- and 12-week mark after randomization, 44% to 49% of the subjects
                                            treated with Sildenafil Cream reported an overall improvement compared to 37% to 44% of the
                                            subjects treated with placebo (P value &lt; 0.01).</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Exploratory
                                            endpoints related to arousal lubrication and achievement and pleasure of orgasm also demonstrated
                                            important differences between the subjects treated with Sildenafil Cream compared to placebo
                                            as measured by change from baseline to the 8-week mark after randomization, at P value =
                                            0.059 and P value = 0.066, respectively (trending toward significance despite the small number
                                            of subjects in each group, n=73 in the Sildenafil Cream intent to treat group and n=64 in
                                            the placebo intent to treat group for these assessments).</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">48.7%
                                            of the subjects treated with Sildenafil Cream reported an increase in their overall satisfaction
                                            with sexual activity measured at the end of the study, compared to 42.6% of the subjects
                                            treated with placebo.</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Summary
of Cited Top Line Data</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
exploratory Phase 2b RESPOND study was underpowered to assess statistical significance, although statistical significance was
achieved on certain assessments. The following table sets forth certain data regarding the co-primary endpoints, the secondary endpoint,
and certain exploratory endpoints:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; width: 38%; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Objective/Endpoint</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; width: 22%; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Measured
    At</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sildenafil<br />

    Cream, N<sup>(1)</sup></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; text-align: left; width: 12%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Placebo,
    N<sup>(1)</sup></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; text-align: left; width: 12%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">P value</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Co-Primary</i>:
    SFQ28 Arousal Sensation Domain</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">End
    of study (week 12)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">70</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">60</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Co-Primary</i>:
    FSDS-DAO Survey (Q14 only (Concerned by difficulties with sexual arousal))</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">End
    of study (week 12)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">70</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">60</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Secondary</i>:
    Proportion of Satisfactory Sexual Events per Month during Double Blind Treatment Period</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
                                            4</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    8</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    12</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">78</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">73</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">71</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">68</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">64</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">61</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">0.04</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</span></p></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Exploratory</i>:
    Arousal Lubrication PROs</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">73</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">64</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">0.059</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Exploratory</i>:
    Orgasm PROs</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">73</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">64</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">0.066</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Exploratory</i>:
    Regarding Concern for FSAD Symptoms<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Weeks
    4 - 12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">78</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&lt;0.01</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Exploratory</i>:
    Regarding Satisfactory Sexual Activity<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Weeks
    4 - 12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">78</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&lt;0.01</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(1)
    The numbers in this column represent the number of subjects included in the assessment at the indicated time point.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(2)
    This exploratory endpoint was measured periodically beginning at week 4 after randomization through the end of the study.</span></td></tr>
  </table>
<p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt">&#160;</p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>Safety</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sildenafil
Cream was generally safe and well-tolerated. There were no treatment related serious adverse events and the majority of treatment related
adverse events were mild in severity.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>Other
Matters</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&#233;
currently continues to anticipate the following upcoming milestone events for its portfolio:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2Q-2023:
                                            First commercial sale in the United States of XACIATO&#8482; (clindamycin phosphate) vaginal
                                            gel, 2%, an FDA-approved product indicated for the treatment of bacterial vaginosis in females
                                            12 years and older;</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Mid-2023:
                                            Initiation of patient recruitment for the planned pivotal Phase 3 clinical study of Ovaprene&#174;,
                                            an investigational hormone-free, monthly intravaginal contraceptive; and</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2023:
                                            Announcement of topline results from the ongoing Phase 1 clinical study of DARE-PDM1, an
                                            investigational proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory
                                            drug, being developed as a vaginally-administered treatment for primary dysmenorrhea.</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>Cautionary
Statement Regarding Forward-Looking Statements</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&#233;
cautions you that all statements, other than statements of historical facts, contained in this report, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221;
&#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221;
&#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;objective,&#8221; or the negative version of these words
and similar expressions. In this report, forward-looking statements include, but are not limited to, statements relating to Sildenafil
Cream&#8217;s potential as a safe and effective therapy for FSAD, Dar&#233;&#8217;s plans for continued clinical development of Sildenafil
Cream, the anticipated regulatory pathway for Sildenafil Cream, the potential for Sildenafil Cream to be the first FDA-approved treatment
for FSAD, the potential market opportunity for Sildenafil Cream, plans and expectations with respect to Dar&#233;&#8217;s product candidates,
including anticipated timing for the first commercial sale of XACIATO, for commencement and conduct of clinical trials and for announcement
of topline results. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar&#233;&#8217;s
actual results, performance or achievements to be materially different from future results, performance or achievements expressed or
implied by the forward-looking statements in this report, including, without limitation, risk and uncertainties related to: the risk
that topline results from a clinical trial, including the Phase 2b RESPOND study, are based on Dar&#233;&#8217;s preliminary analysis
of key efficacy and safety data and, following a comprehensive review of the study data, topline results may not accurately reflect the
complete results from the study and the differences between topline results and complete results may be significant and may adversely
impact the continued clinical development of the investigational product, including anticipated time and expense of continued development;
the risk that data from the Phase 2b RESPOND study, which assessed multiple patient reported outcomes at 4, 8 and 12 weeks after randomization,
may not be predictive of results of any future clinical study that assesses safety and efficacy of Sildenafil Cream at time points beyond
12 weeks after randomization, and the double-blind dosing period the FDA may require for a pivotal Phase 3 study of Sildenafil Cream
is unknown at this time; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors
may not accept or agree with Dar&#233;&#8217;s interpretation of or conclusions regarding the study data; Dar&#233;&#8217;s ability
to raise additional capital when and as needed to advance its product candidates, execute its business strategy and continue as a going
concern; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of
success in subsequent clinical and/or nonclinical studies of that candidate; the risk that development of a product candidate requires
more clinical or nonclinical studies than Dar&#233; anticipates; Dar&#233;&#8217;s ability to develop, obtain FDA or foreign regulatory
approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting
and completing clinical trials of a product candidate; Dar&#233;&#8217;s ability to design and conduct successful clinical trials,
to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety
concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Dar&#233;&#8217;s dependence on third parties
to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the loss of, or inability to attract,
key personnel; the effects of the COVID-19 pandemic, macroeconomic conditions and geopolitical events on Dar&#233;&#8217;s operations,
financial results and condition, and ability to achieve current plans and objectives, including the potential impact of the pandemic
on Dar&#233;&#8217;s ability to timely commence, enroll, conduct and report results of its clinical trials and on the ability of third
parties on which Dar&#233; relies to assist in the conduct of its business to fulfill their contractual obligations to Dar&#233;;
the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; the risk that
developments by competitors make Dar&#233;&#8217;s product or product candidates less competitive or obsolete; difficulties establishing
and sustaining relationships with development and/or commercial collaborators; failure of Dar&#233;&#8217;s product or product candidates,
if approved, to gain market acceptance or obtain adequate coverage or reimbursement from third-party payers; Dar&#233;&#8217;s ability
to retain its licensed rights to develop and commercialize a product or product candidate; Dar&#233;&#8217;s ability to satisfy the
monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and
related intellectual property related to its product and product candidates; Dar&#233;&#8217;s ability to adequately protect or enforce
its, or its licensor&#8217;s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar&#233;&#8217;s
product candidates which could expose its products to competition from other formulations using the same active ingredients; product
liability claims; governmental investigations or actions relating to Dar&#233;&#8217;s product or product candidates or the business
activities of Dar&#233;, its commercial collaborators or other third parties on which Dar&#233; relies; the impact of pharmaceutical
industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment;
cyber attacks, security breaches or similar events that compromise Dar&#233;&#8217;s technology systems or those of third parties on
which it relies and/or significantly disrupt Dar&#233;&#8217;s business; and disputes or other developments concerning Dar&#233;&#8217;s
intellectual property rights. Dar&#233;&#8217;s forward-looking statements are based upon its current expectations and involve assumptions
that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by
these cautionary statements. For a detailed description of Dar&#233;&#8217;s risks and uncertainties, you are encouraged to review
its documents filed with the SEC including Dar&#233;&#8217;s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned
not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar&#233; undertakes
no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made,
except as required by law.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.75in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Item
    9.01</b></span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; width: 0.75in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: justify; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">99.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><a href="ex99-1.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Press release issued on June 5, 2023</span></a></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Arial, Helvetica, Sans-Serif"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>DAR&#201;
                                            BIOSCIENCE, INC.</b></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1.5pt; vertical-align: top; width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated:
    June 5, 2023</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1.5pt; vertical-align: top; width: 5%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; width: 45%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><i>/s/
    Sabrina Martucci Johnson</i></span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sabrina
    Martucci Johnson</span></td></tr>
  <tr style="font: 10pt Arial, Helvetica, Sans-Serif">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">President
    and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5lpq2KtJHixaxihQRX6NdJdhmyyb+HclbGlvEZWFZZr4ZIQYip4WukeEwKwvYYdPWyiGUeEZGc0LvyJarFPwt8aKtY2Vc9/7AjDyDnhmH0fTohc561xarFORkKEfDOAGZpEkM27UIvnpG5qwrNE6rGpSpYMvUskan+NUn7NSTDDWvrmqPbDWZFKJQ9vIbYhnFsKG7ehBfLRRFJoJBN4HImW7tt+ZmHTUwr7HxXbZH/xt8ABq7SU0= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white; color: #35495E"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white; color: #35495E"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Dar&eacute;
Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female
Sexual Arousal Disorder</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white; color: #35495E"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Sildenafil
Cream-treated patients showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the
Arousal-Sensation Domain of the Sexual Function Questionnaire</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white; color: #35495E"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Sildenafil
Cream-treated patients also showed improvements in the secondary endpoint and pre-specified exploratory endpoints that evaluated sexual
satisfaction, arousal lubrication, and achievement and pleasure of orgasm</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white; color: #35495E"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Data
support continued development of Sildenafil Cream and selection of proposed primary endpoint assessments for a Phase 3 study</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white; color: #35495E"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Sildenafil
Cream has the potential to be the first FDA-approved treatment for female sexual arousal disorder</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white; color: #35495E"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SAN
DIEGO, June 5, 2023 (GLOBE NEWSWIRE) &mdash; Dar&eacute; Bioscience, Inc. (NASDAQ: DARE), a leader in women&rsquo;s health innovation,
and its collaborator Strategic Science &amp; Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today
announced positive topline data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream)
as a treatment for female sexual arousal disorder (FSAD). The exploratory study was designed to test the sensitivity of several patient
reported outcome (PRO) efficacy endpoints and their ability to determine a treatment effect of Sildenafil Cream compared to placebo to
inform the ongoing development of Sildenafil Cream. The study also served as a validation study of exploratory endpoints that could be
candidate endpoints in a Phase 3 study of Sildenafil Cream. Although the exploratory study was underpowered to assess statistical
significance, certain endpoints achieved statistical significance.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">FSAD
is the inability to reach or maintain a sufficient physical response to sexual stimulation and, of the various types of female sexual
dysfunction disorders, FSAD is most analogous to erectile dysfunction (ED) in men. Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor,
is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra&reg; for the treatment of
ED in men. Sildenafil Cream is an investigational proprietary topical cream formulation of sildenafil specifically designed to increase
blood flow to the genital tissue in women. If development is successful, Sildenafil Cream has the potential to be the first FDA-approved
treatment for FSAD. Market research suggests that 16% of women in the U.S. ages 21 to 60, or approximately 10 million women, are distressed
from experiencing symptoms associated with FSAD, including lack of or low sexual arousal, and are actively seeking solutions to improve
their condition. In comparison, the prevalence of complete ED in men is estimated to be about 5% of men at age 40, increasing to about
15% at age 70.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&ldquo;We
are very pleased with the topline data from the Phase 2b RESPOND study. Although the study was underpowered to assess statistical
significance, we saw statistically significant results for certain of the endpoints, and the data indicate that, as compared to placebo,
Sildenafil Cream had a therapeutic effect based on several PROs,&rdquo; said Sabrina Martucci Johnson, President and CEO of Dar&eacute;
Bioscience. &ldquo;Because there are currently no FDA-approved treatments for FSAD, there are no efficacy endpoints that have been previously
approved for use in a Phase 3 pivotal study for potential treatment for FSAD &ndash; but with the data from the Phase 2b RESPOND study
we believe certain of the primary, secondary, and exploratory endpoints could be candidate endpoints in a Phase 3 study of Sildenafil
Cream. Having now completed this pioneering work in the field of FSAD, we look forward to reviewing the data with the FDA, including
discussing the data from assessments as early as the 4- and 8-week mark after randomization, and continuing the development of Sildenafil
Cream, including our objective of initiating the first ever Phase 3 pivotal study for the treatment of FSAD. Following
clinical development, Dar&eacute; intends to leverage the existing safety and efficacy data on the active ingredient in Sildenafil Cream
to utilize the FDA&rsquo;s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream in the U.S.&rdquo;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&ldquo;The
FDA has not approved any pharmacologic options for FSAD, a condition which significantly compromises a woman&rsquo;s ability to have
a pleasurable sexual experience,&rdquo; commented Dr. Sheryl Kingsberg, Division Chief of Behavioral Medicine, Department of OBGYN, University
Hospitals Cleveland Medical Center, Ohio, and Past President of The International Society for the Study of Women&rsquo;s Sexual Health,
as well as co-editor of the Textbook of Female Sexual Function and Dysfunction: Diagnosis and Treatment. &ldquo;Based on the topline
data from the Phase 2b RESPOND study I am very excited about the potential for this topical Sildenafil Cream to address this critical
unmet need in women&rsquo;s sexual health. Leveraging the known therapeutic benefit of the active ingredient in Viagra&reg;, sildenafil,
in a cream formulation to stimulate increased blood flow to the genital tissue, Sildenafil Cream may offer women a safe, effective and
&lsquo;on demand&rsquo; solution to difficulties with sexual arousal allowing for a more intense and enjoyable sexual experience.&rdquo;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Unlike
the oral formulations of PDE-5 inhibitors, Sildenafil Cream is designed to be applied locally to the vulvar-vaginal tissue prior to sexual
activity to facilitate vasodilation and increase blood flow directly to the genital tissue to improve the physical arousal response to
address the lack of those genital arousal sensations commonly associated with FSAD. Increasing blood flow to the genital tissue, as Sildenafil
Cream is designed to do, has the potential to improve genital arousal response and overall sexual experience for women. This is similar
to the way ED medications work in men by directing blood flow to the genitals when taken prior to sexual activity.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&ldquo;The
topline data from the Phase 2b RESPOND study represent an important milestone in the field of female sexual dysfunction,&rdquo;
said Dr. Andrew Goldstein, Medical Advisor of Dar&eacute; Bioscience and Past President of The International Society for the Study of
Women&rsquo;s Sexual Health, as well as co-editor of the Textbook of Female Sexual Function and Dysfunction: Diagnosis and Treatment.
&ldquo;It is exciting to be working at the cutting edge of research focused on women&rsquo;s sexual health and to advance a potential
first-in-category treatment option for women suffering with FSAD.&rdquo;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&ldquo;It
is encouraging to see sponsors such as Dar&eacute; and SST developing endpoints that will foster approval of new medicines for women
in FSAD. The previously completed <U>content validation study</U> and the exit interviews completed as part of the Phase 2b RESPOND study
are significant steps to gaining regulatory approval of endpoints in this area. I look forward to continuing our collaboration by using
the Phase 2b RESPOND study data to conduct psychometric analyses to further refine the measures and resulting endpoints for use in
a Phase 3 pivotal study,&rdquo; said Tara Symonds, Ph.D., Managing Director, UK, and Chief Scientific Officer at Clinical
Outcomes Solutions, who is an advisor to Dar&eacute; and SST and has extensive expertise in the development and validation
of PROs for sexual health clinical trials, including establishing and leading Pfizer&rsquo;s PRO Center of Excellence earlier
in her career. </FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
plans to submit data from the Phase 2b RESPOND clinical study of Sildenafil Cream for publication in a peer-reviewed journal.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>About
the Exploratory Phase 2b RESPOND Study</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Study
Design</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
exploratory Phase 2b RESPOND study was a multi-center, double-blind, randomized, placebo-controlled study to evaluate the efficacy and
safety of Sildenafil Cream in premenopausal patients with FSAD. The study was a first of its kind Phase 2b clinical study that includes
PRO instruments to screen eligible women with FSAD and included two co-primary endpoints, a secondary endpoint, and a number of exploratory
endpoints to measure, among other things, improvement in localized genital sensations of arousal, reduction in the distress that women
experience with FSAD and satisfactory sexual events. There are no FDA-approved treatments for FSAD and thus there are no efficacy endpoints
that have been previously validated in a Phase 3 pivotal study for potential treatments for FSAD.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
FDA requested that any PROs for use in the assessment of efficacy in a Phase 3 study be adequately validated. Part of that validation
of the PROs includes exit interviews performed as part of the Phase 2b RESPOND study to better understand qualitatively what constitutes
a meaningful change to the subjects. These qualitative assessments of meaningful change were utilized to determine which endpoints achieved
meaningful improvement in the Sildenafil Cream group. Additional psychometric analyses using the Phase 2b RESPOND study dataset
is planned to further refine and validate the measures to inform the most appropriate endpoints for use in a Phase 3 pivotal
study. </FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
Phase 2b RESPOND study began with 99 subjects in the Sildenafil Cream intent to treat population and 93 subjects in the placebo intent
to treat population, with 70 subjects in the Sildenafil Cream intent to treat population and 60 subjects in the placebo intent to treat
population completing the study, and therefore was underpowered to assess statistical significance. During the study, participants
used Sildenafil Cream and a placebo cream in their home setting and documented their experience using PRO instruments. The study evaluated
Sildenafil Cream compared to placebo cream over 12 weeks of dosing following both a non-drug and placebo run-in period.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>Study
Efficacy Results and Safety</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Summary
of Topline Data</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A
co-primary endpoint of the Phase 2b RESPOND study was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by
change from baseline to the end of the study in the Arousal-Sensation Domain of the 28-item Sexual Function Questionnaire (SFQ28). The
endpoint did not achieve statistical significance. However, the change at the end of the study in the group treated with Sildenafil Cream
was consistent with how women reported meaningful improvement in an exit interview at the end of the study.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
other co-primary endpoint was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to
the end of the study in the score for feeling concerned by difficulties with sexual arousal. The change was assessed using the previously
validated Female Sexual Distress Scale &ndash; Desire, Arousal and Orgasm (FSDS-DAO) Survey. This assessment did not differentiate Sildenafil
Cream from placebo.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
secondary endpoint of the study was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline
to the end of the study in the number of satisfactory sexual events based on the subjects&rsquo; response to a question answered and
recorded via electronic diary within 24 hours after each sexual event. The endpoint was selected because it can serve as a primary endpoint
in a Phase 3 study based on the FDA draft 2016 guidance document for female sexual dysfunction. When measured at the 4- and 8-week mark
after randomization, subjects treated with Sildenafil Cream had a higher proportion of satisfying sexual events during the prior month
(68.6% and 74.1% at the 4- and 8-week mark, respectively) compared to those treated with placebo (47.9% and 67.9% at the 4- and 8-week
mark, respectively) (week 4 P value = 0.04).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
exploratory endpoints (selected based on the Content Validity study conducted by SST and Dar&eacute;) included endpoints related to genital
arousal, genital blood flow, lubrication, orgasm, concerns about difficulties with sexual arousal, and other assessments including questions
regarding satisfying sexual events. The exploratory endpoints were assessed at multiple periods over the course of the study via electronic
diary.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">An
                                            exploratory endpoint regarding concerns about difficulties with sexual arousal differentiated
                                            Sildenafil Cream versus placebo. Specifically, when asked about their overall impression
                                            of change regarding their concerns about difficulties with sexual arousal, women treated
                                            with Sildenafil Cream were more likely to report an overall improvement. Based on responses
                                            to the question at the 4-, 8- and 12-week mark after randomization, 44% to 49% of the subjects
                                            treated with Sildenafil Cream reported an overall improvement compared to 37% to 44% of the
                                            subjects treated with placebo (P value &lt; 0.01).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Exploratory
                                            endpoints related to arousal lubrication and achievement and pleasure of orgasm also demonstrated
                                            important differences between the subjects treated with Sildenafil Cream compared to placebo
                                            as measured by change from baseline to the 8-week mark after randomization, at P value =
                                            0.059 and P value = 0.066, respectively (trending toward significance despite the small number
                                            of subjects in each group, n=73 in the Sildenafil Cream intent to treat group and n=64 in
                                            the placebo intent to treat group for these assessments).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
<TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">48.7%
                                            of the subjects treated with Sildenafil Cream reported an increase in their overall satisfaction
                                            with sexual activity measured at the end of the study, compared to 42.6% of the subjects
                                            treated with placebo.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Summary
of Cited Top Line Data</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
exploratory Phase 2b RESPOND study was underpowered to assess statistical significance, although statistical significance was
achieved on certain assessments. The following table sets forth certain data regarding the co-primary endpoints, the secondary endpoint,
and certain exploratory endpoints:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; width: 38%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Objective/Endpoint</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; width: 22%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Measured
    At</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; width: 12%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sildenafil<BR>

    Cream, N<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; width: 12%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Placebo,
    N<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; width: 12%; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">P
    value</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Co-Primary</I>:
    SFQ28 Arousal Sensation Domain</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">End
    of study (week 12)</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">70</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">60</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Co-Primary</I>:
    FSDS-DAO Survey (Q14 only (Concerned by difficulties with sexual arousal)) </FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">End
    of study (week 12)</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">70</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">60</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Secondary</I>:
    Proportion of Satisfactory Sexual Events per Month during Double Blind Treatment Period</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
                                            4</FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    8</FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    12</FONT></P></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">78</FONT> </P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">73</FONT> </P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">71</FONT> </P></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">68</FONT> </P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">64</FONT> </P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">61</FONT> </P></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">0.04</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&gt;0.05</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Exploratory</I>:
    Arousal Lubrication PROs</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    8</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">73</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">64</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">0.059</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Exploratory</I>:
    Orgasm PROs</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Week
    8</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">73</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">64</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">0.066</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Exploratory</I>:
    Regarding Concern for FSAD Symptoms<SUP>(2)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Weeks
    4 - 12</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">78</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">68</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&lt;0.01</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Exploratory</I>:
    Regarding Satisfactory Sexual Activity<SUP>(2)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Weeks
    4 - 12</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">78</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">68</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&lt;0.01</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(1)
    The numbers in this column represent the number of subjects included in the assessment at the indicated time point.</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Arial, Helvetica, Sans-Serif; vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(2)
    This exploratory endpoint was measured periodically beginning at week 4 after randomization through the end of the study.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>Safety</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sildenafil
Cream was generally safe and well-tolerated. There were no treatment related serious adverse events and the majority of treatment related
adverse events were mild in severity.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>About
FSAD and Sildenafil Cream, 3.6%</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">FSAD
is distinct from hypoactive sexual desire disorder (HSDD) in women, which is characterized primarily by a lack of sexual desire. FSAD
is a condition characterized primarily by a persistent or recurrent inability to attain or maintain sufficient genital arousal (an adequate
lubrication-swelling response) during sexual activity, frequently resulting in distress or interpersonal difficulty. As with ED in men,
FSAD is associated with insufficient blood flow to the genitalia.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Market
research suggests that 16% of women in the U.S. ages 21 to 60, or approximately 10 million women, are distressed from experiencing symptoms
associated with FSAD, including lack of or low sexual arousal, and are actively seeking solutions to improve their condition. In comparison,
the prevalence of complete ED in men is estimated to be about 5% of men at age 40, increasing to about 15% at age 70. Dar&eacute; believes
the potential market opportunity for an FDA-approved treatment for FSAD is comparable in size to the market for FDA-approved treatments
for ED in men.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sildenafil
Cream, 3.6% is an investigational proprietary cream formulation of sildenafil, a PDE-5 inhibitor, designed for topical administration
to the vulvar-vaginal tissue to increase genital blood flow and provide improvements in the female genital arousal response, while avoiding
systemic side effects observed with oral formulations of sildenafil. Sildenafil Cream has been previously evaluated in Phase 1 and Phase
2a clinical studies. In a Phase 1 clinical study in 20 healthy post-menopausal women, topical Sildenafil Cream was safe and well tolerated
at clinically relevant doses, and study subjects reported favorable product characteristics: easy to use and readily absorbed. In a Phase
2a study in women with FSAD (15 pre-menopausal and 16 post-menopausal), Sildenafil Cream increased measurable blood flow to the genital
tissue compared to placebo cream. Further, data from a thermography study in six healthy women demonstrated significantly greater increases
in genital temperature after administration of Sildenafil Cream compared to placebo cream, indicating a positive impact on genital blood
flow during the 30-minute testing session, with statistical separation from placebo within the first 15 minutes of dosing.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>About
Dar&eacute; Bioscience</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
Bioscience is a biopharmaceutical company committed to advancing innovative products for women&rsquo;s health. The company&rsquo;s mission
is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women&rsquo;s health and
well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health,
menopause, sexual health and fertility.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;&rsquo;s
first FDA-approved product, XACIATO&trade; (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment
of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO
is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Dar&eacute;&rsquo;s portfolio also includes
potential first-in-category candidates in clinical development: Ovaprene&reg;, a novel, hormone-free monthly intravaginal contraceptive
whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil
to treat female sexual arousal disorder utilizing the active ingredient in Viagra&reg;; and DARE-HRT1, a combination bio-identical estradiol
and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Dar&eacute;&rsquo;s full portfolio of
women&rsquo;s health product candidates, and Dar&eacute;&rsquo;s mission to deliver differentiated therapies for women, please visit
www.darebioscience.com.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors
section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar&eacute;
will use these channels to distribute material information about the company, and may also use social media to communicate important
information about the company, its finances, product and product candidates, clinical trials and other matters. The information Dar&eacute;
posts on its investor relations website or through social media channels may be deemed to be material information. Dar&eacute; encourages
investors, the media, and others interested in the company to review the information Dar&eacute; posts in the Investors section of its
website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the
company may use to communicate information will be posted in the Investors section of Dar&eacute;&rsquo;s website.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dar&eacute;
cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;design,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect,&rdquo;
&ldquo;could,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo;
&ldquo;contemplate,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;objective,&rdquo; or the negative version of these words
and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to Sildenafil
Cream&rsquo;s potential as a safe and effective therapy for FSAD, Dar&eacute;&rsquo;s plans for continued clinical development of Sildenafil
Cream, the anticipated regulatory pathway for Sildenafil Cream, the potential for Sildenafil Cream to be the first FDA-approved treatment
for FSAD, and the potential market opportunity for Sildenafil Cream. Forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause Dar&eacute;&rsquo;s actual results, performance or achievements to be materially different from future
results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without
limitation, risk and uncertainties related to: the risk that topline results from a clinical trial, including the Phase 2b RESPOND study,
are based on Dar&eacute;&rsquo;s preliminary analysis of key efficacy and safety data and, following a comprehensive review of the study
data, topline results may not accurately reflect the complete results from the study and the differences between topline results and
complete results may be significant and may adversely impact the continued clinical development of the investigational product, including
anticipated time and expense of continued development; the risk that data from the Phase 2b RESPOND study, which assessed multiple patient
reported outcomes at 4, 8 and 12 weeks after randomization, may not be predictive of results of any future clinical study that assesses
safety and efficacy of Sildenafil Cream at time points beyond 12 weeks after randomization, and the double-blind dosing period the FDA
may require for a pivotal Phase 3 study of Sildenafil Cream is unknown at this time; the risk that the FDA, other regulatory authorities,
members of the scientific or medical communities or investors may not accept or agree with Dar&eacute;&rsquo;s interpretation of or conclusions
regarding the study data; Dar&eacute;&rsquo;s ability to raise additional capital when and as needed to advance its product candidates,
execute its business strategy and continue as a going concern; the risk that positive findings in early clinical and/or nonclinical studies
of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; the risk
that development of a product candidate requires more clinical or nonclinical studies than Dar&eacute; anticipates; Dar&eacute;&rsquo;s
ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated
timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate; Dar&eacute;&rsquo;s ability
to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints,
to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates;
Dar&eacute;&rsquo;s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial
product; the loss of, or inability to attract, key personnel; the effects of the COVID-19 pandemic, macroeconomic conditions and geopolitical
events on Dar&eacute;&rsquo;s operations, financial results and condition, and ability to achieve current plans and objectives, including
the potential impact of the pandemic on Dar&eacute;&rsquo;s ability to timely commence, enroll, conduct and report results of its clinical
trials and on the ability of third parties on which Dar&eacute; relies to assist in the conduct of its business to fulfill their contractual
obligations to Dar&eacute;; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally;
the risk that developments by competitors make Dar&eacute;&rsquo;s product or product candidates less competitive or obsolete; difficulties
establishing and sustaining relationships with development and/or commercial collaborators; failure of Dar&eacute;&rsquo;s product or
product candidates, if approved, to gain market acceptance or obtain adequate coverage or reimbursement from third-party payers; Dar&eacute;&rsquo;s
ability to retain its licensed rights to develop and commercialize a product or product candidate; Dar&eacute;&rsquo;s ability to satisfy
the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents
and related intellectual property related to its product and product candidates; Dar&eacute;&rsquo;s ability to adequately protect or
enforce its, or its licensor&rsquo;s, intellectual property rights; the lack of patent protection for the active ingredients in certain
of Dar&eacute;&rsquo;s product candidates which could expose its products to competition from other formulations using the same active
ingredients; product liability claims; governmental investigations or actions relating to Dar&eacute;&rsquo;s product or product candidates
or the business activities of Dar&eacute;, its commercial collaborators or other third parties on which Dar&eacute; relies; the impact
of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health
care cost containment; cyber attacks, security breaches or similar events that compromise Dar&eacute;&rsquo;s technology systems or those
of third parties on which it relies and/or significantly disrupt Dar&eacute;&rsquo;s business; and disputes or other developments concerning
Dar&eacute;&rsquo;s intellectual property rights. Dar&eacute;&rsquo;s forward-looking statements are based upon its current expectations
and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified
in their entirety by these cautionary statements. For a detailed description of Dar&eacute;&rsquo;s risks and uncertainties, you are
encouraged to review its documents filed with the SEC including Dar&eacute;&rsquo;s recent filings on Form 8-K, Form 10-K and Form 10-Q.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.
Dar&eacute; undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date
on which they were made, except as required by law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Contacts:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Investors
on behalf of Dar&eacute; Bioscience, Inc.:<BR>
Lee Roth<BR>
Burns McClellan<BR>
lroth@burnsmc.com<BR>
646.930.4406 </FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">OR</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Media
on behalf of Dar&eacute; Bioscience, Inc.:<BR>
Jake Robison<BR>
Evoke Canale<BR>
jake.robison@evokegroup.com<BR>
619.849.5383</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Source:
Dar&eacute; Bioscience, Inc.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dare-20230605.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCBmbP9z5Z8OekhvWBxbWnKryQqHcrLfC5VxxQW0VIB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:DARE="http://darebioscience.com/20230605" elementFormDefault="qualified" targetNamespace="http://darebioscience.com/20230605">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://darebioscience.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="dare-20230605_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="dare-20230605_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>dare-20230605_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>dare-20230605_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://darebioscience.com/role/Cover" xlink:href="dare-20230605.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://darebioscience.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139755440279056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  05,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Dare Bioscience, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4139823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3655
Nobel Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San
Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-7655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DARE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dare-20230605.xsd" xlink:type="simple"/>
    <context id="From2023-06-05to2023-06-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2023-06-05</startDate>
            <endDate>2023-06-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-06-05to2023-06-05">0001401914</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-06-05to2023-06-05">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="From2023-06-05to2023-06-05">Dare Bioscience, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="From2023-06-05to2023-06-05">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-06-05to2023-06-05">2023-06-05</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-06-05to2023-06-05">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-06-05to2023-06-05">001-36395</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-06-05to2023-06-05">20-4139823</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-06-05to2023-06-05">3655 Nobel Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-06-05to2023-06-05">Suite 260</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-06-05to2023-06-05">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-06-05to2023-06-05">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-06-05to2023-06-05">92122</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-06-05to2023-06-05">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-06-05to2023-06-05">926-7655</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-06-05to2023-06-05">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-06-05to2023-06-05">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-06-05to2023-06-05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-06-05to2023-06-05">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-06-05to2023-06-05">Common     stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-06-05to2023-06-05">DARE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-06-05to2023-06-05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-06-05to2023-06-05">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?L0:.*VLG>(V_)89<OL2;9A<\Z.KQP:AA_%\.OX=8ZH\G9[DZ;<IUVN7I5]
MP6Z<4V1,UL\A+GBTKOR#;:W[B> K<W<T).$K$ HNKT!7[W;=NX%56;'372H+
M^^;B<,,9U+R[ +Y?*67?!F[S7/[V,?H!4$L#!!0    ( *] Q5:?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( *] Q58'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ KT#%5CSC
M59WN    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ KT#%5IE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "O0,56-R?*Y% $   '
M$0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ KT#%5I^@&_"Q @  X@P   T              ( !DPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "O0,56EXJ[',     3 @  "P
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52P4&      D "0 ^ @  YQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  form8-k.htm 22</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>dare-20230605.xsd</File>
    <File>dare-20230605_lab.xml</File>
    <File>dare-20230605_pre.xml</File>
    <File>ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dare-20230605_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dare-20230605_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dare-20230605.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "DARE",
   "nsuri": "http://darebioscience.com/20230605",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-06-05to2023-06-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://darebioscience.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-06-05to2023-06-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://darebioscience.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001493152-23-020081-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-020081-xbrl.zip
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MH*T)B 2K,8"&@[9XIM0+$3,Q,G&<SFE,=C^3/=@N0^>6"<!F&PI-%! 5=F<
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M!@&=JU[NM*EZW"H*HO>[G.DD5%K4%CO&8L'2)$KRA*Y_$2>?/,&V5ME$KH"
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M7H::%:"5?$:LJ@+])BM!12VVWR]O;KH6G\1FM4G\M<(9$5O^"U!+ P04
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M0GV>2QAK^MU64/0!@C)"/ER<B<>@WL[N$A(@YY*J'&ZTV=8U.4Y"C&2DTUG
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M<D=?&HB1V&4!CY>+0\E1)@M Q'&V1ZJ6Y[(OA:RQ*<@/RQ&L\+;8VQWR-I]
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MT"7R4$G0S@HN(!JEY-]P+^HZ&!FAT&NJ80F(TE%@8B@A>GM$%EA*MPA&%VS
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M/E?7QL BALH;#J'Y0IODPS8N]JT9)IZQ8]Q?*;/)9>H<= PS478P8[*51#1
M;*OJR1V$)UC:C0P:$UH[S@V[TIZ%OG#\;DE)+='=A;;LHI' %.0I%J!:EC1S
MC^FM(Y!7S5H1NSE)QN=>P>71-B:W4O0C4RN1 @:5Y[&V)Y2BZ3BX"2<2A5#>
M_%C;:476E6?;F(V_$:(NDLB#J2,/&?"*OKWJ[;%Q,QG&@9G2-V.L;H*59A7G
M^<"YA&'D5S_@=VGU0Y,B4U>I:+MGT4)C[X%2LK!.@;!DV]#\%YH-7ZGSXER7
M5G?5@049[ B+B2B5?2Q2$(#P*1DSFS^02$&X $K$UM$00;L<6TNQ6DA4AA-Q
M%*MPKZ -\2L0S"& LB9P1RP\2=(X)1=+-MOD$F!.L;MCO1$VA;.]5K$W]T1$
M)L]*<E#;WNA66BK@Z,J9[!QPZ]>P<1:L,G!9Y]^ND]KVPL=S@H)U>*V<V5(5
MAZHD_2#,+XK-A54)>)33F04-+E":8)=^!4ZAVGFS+^NE,VTCH*A7I:>'Q4 =
MQ/%%A-E )TTNZ;B8,SR\T41P#-!<!K@NH4]4'4DF"Q; 2RDA4(P*<!BHF(-1
M.>GMV7E%&QPE7@UZ]CA%%B!06U771%Z%#&8O2L-21C#BM[%E@8R@XJJ.>;:^
M58=L@J4L"XQ'E$_5L_Z_>_+;UF;_WTR5^^OG0;?SNY#D!D^OA+?N=M' 22HU
M,VY@79+UD^[B;/E,!Y^D%W)0.0/L=%?"0)\L["D-9((&S7T:7*5:$#;+<51$
M;8QYCQ77ZDA^SEMNGD0)F_J2G"*JRO$;D]&\YHQH['?Z,]"O!,H<@22_[12B
M.I_C1T'N< #'S.-@?E^:\]7H? WM3<;ZQ<TG];9,J5?JB1II/0GBT9+:\O9%
M]=3;)!R\V'^%@[O>::T^DH&1OUZ5&:GK]^'KF*Q'D,B',0&ZR3^'^&H:HC14
M/M[_^')W9W?P_/'F8&=G<[?1W?S&SM1M6='CCS>?QMLRE^]1VWEYR?@7X@8?
MTR$.19!/CLY2^N@U$HA:/OF#KAED<LT_-;[&*<>S6DAVMYX/GNT\'SQY_.SQ
MS9^IV[*B)P2K0OUBW<9/6<:;/XP_<2KA[IXZ%E#]0KT+"-K<UZ[^?2HTESGV
MT:OCP]]A:1_]>/K^W<O_!U!+ P04    " "O0,56_(.'EG$M  ##0P$ "P
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M: 5"N$P S4E4[SUHZ9IX/0)FC%/J&VBCYX%*+OJ!! +N,^':O@<6H2H O$H
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M Z_ W)?;&_?.]]*;?C@G]^56C0X<3@+&:$+8<-<FD4-E$D87NF2A2Q:ZY#Y
MUG9*VW].+!HFD,UIBU.ZF%"8Y,*G')%D_VAB5R3C5*"$Q'#3\/[)\#9O(:,R
M:E7<P9B>U3VR9SI+&31GR3VS2Z8ZDK@ 5Y[/WC]"3M5BXWH*N>P_EZ(]K@EV
MN[R49&MCNKA.YDY;"#H0.TA@UOI4"7UJ(DP2P'6V9B;*,>;X'PF/T0. .L,U
M[BTW\CNKJ@6_.DC[_.Y(F.+=\Z,W>Z8K&XR[N7UZ!Z%)RX$_L=XP9/B0*_O'
M3J)RQQP>Z7+_L;!5JX^!X _&!-%3/'QVZ,T?/G^O-88:2SM,KTQ,8FF^: 9L
MG80/3M<<$3A]H2+_8+6"I2C@Q^^(_BS,4T7^N39Q"WJ*"US/%-<Z&#3+"G&@
M4@$]&%!Q;52K7K#'@G9SM5JN%:H;.X7JYN;:PZ\,FJ[-?^05S[7UA>;]GBD\
M@^GL23[L<&[\S"I#3#.HZ]I)A1AM'>ODM:$"GO-4V&*[/*^0;\TMY'^UPWV,
M(S^VM/C< ??[28N(.#'>Y,6SU8^5&CB'&$\_FB2W?VUV_+@0)PMQ\K0@_U7B
MY*D:'Y=Q@"<E6,XS^?.7Z9,0YAB/OOT/T_C8!TJ:-[GT=;J!"VQ3O-KJ*CZ)
MS,XIW6^64N;I!7,_@W":+.1>RP2>"!5/;UHY(;(G"NE@ 7;F =QY1&REFH+W
MT53!/*;+;T^%!G_]/*9'I;]^+ML;SV,>SVI-*@N)<D\3?"%1GMQ<MJ9BPOWZ
M>3RK-5E(E'MB"D\2/X\U?T[T.Q*PF._9/.^5^3VCTZGT_504*=Z[>I]*P\>;
M?.<AV)P7.YBS0&?*NYDSR%-6U)Q!3N<=%I'ENZ2"N=5I(0@6@N!Y"X*MK=]Z
MQSJ?^R^2M&.S0SVHUW#9[_I@I"F=>56]*_/J"<H(<[JBQHKIH/B<4>WVW,JX
MK;F%'$^+EZD*W,)JN(_<R-N-/C2GI!:B8R$Z%J(#14?^N;QD8W@0AWG($9<'
MGER9J&AG!5![! V;@;P7<J=_%FBULJ:!NTKN!345/21>Z.Q$7;J].1"*SG!G
M+P\='#0WEWZ-UDHR!SFE:V-P!(^*R:Y@='!E])SE+T'E\*5V<[Z>U60]I<J_
M *F7OC5!7U$FZ=HAK%$C79?J#H3,7,&9<U<"K&A )_GNOI[[GG52 6?KE?+V
MGS]$7"KA(\O9/Y<\,DW%/LWS@%-.@*."%E,_6/NT3\[.FME&[]Y&WC*UN['H
M-B"=[M#H@8HIAIXC ET)CNH!ZANOTO4 D^M=%')EI+!*BL + \U5OJ90$DSQ
M7R^0NF3GR,?+2T-?Z8NU %0J\HVW_\.GS^J"P;NOTMU8W)H[W5MS-Q:WYBYN
MS;U3WS2?3>%I/153$?X#QQJ::LZG--=75*1*HEE1@)=QZDN)J0@9E5?@\!L+
M]YFKM 97142^!28L_("!A0H]-]&0&)W%4M5X' #:2^^YWNRPN'-J<>?4PX&L
M?BQ6R]6-O<G.>QQ3,7A@O:X(+(EWOF )C;AVG4NW_UR&P*Y4+OB?PZ.3PZNS
MO_[8J>U4]]DJ5O*S>;=O827*CJ?\#K1<8S<<Z(L[DT'2%C#9ZI]X-3B6^R@F
MQ;?A'[S4/!6E&"DSB+ UN07B'Z= PWM*4JA$%P69\.*I2I7U!0^T3>^!&Q'L
MCSC.,[[Z+DLGB_OP%K)ICF73!VD_1#B=@/R1215V,!JD]J2M())A4O;'W&9)
M!;_C<J1Q>=*DU&A2EOOLAOM@F @@^.W:?F$R@.BVO1N\C[K-3>7RCA=TP5@I
MM@(A"KIZCX.EG,* &S%(!E# +>'CS4#[*%,6PF0A3!;"Y*&&SN2"Y-!UO<BU
M1&PKA*9$;"!4Y*"+@7<2HQSQW+9'Q;Y)?E1RY$?]\*)1/*]_J*"A,AD4PZ(#
M2X0%4H1XLUVG;P<>F$ HT;IQ0788#DP>QVL)EUL%70E<@9'C29OJ$X82F+CE
M\&[W ==68T7Q FL**D:M"S'CU9Y8G\T(+J=?Y#;X9%@UE.X13,PM%+OQ97UV
M'_>2O"#H"/[H%P0_"<$V)^ZG#I8<\8C(#\F%#'M:T$%NP[$7X.W7Q?>>=TVY
M#G&;>0^L/*.P5SK,HI=3L;X7@03C(:.+?Y-%*Y@J2_#*33U&T=(!OO8"DFZ8
MRZ*HBA/>IQEO%4ME[AD&T:/KMA)E.(8R!KV5EI>.Q[XLT,:&UP75#S(51P%(
MFN!C(I/*EM3WPX"$Z2JF(JN#(@@+65;+^TWAX&VC!?JSLA\_[O+^\*.>=)SX
MV?*2>8C"%B3CR/=Q0&KX^2 V-?S&%G@5ZO!37:=^^*FXQ3OE1X"QO,@9:8MF
MZ\@S+Z0B-L[("RQF/^@Y?JR$N!YYULD;K9=^F (,IM'UG9QI@X+Z5XR." JK
M+4:>>O'=E\D+8YN[ C7>C:"B.D:MZ;OE>UY@*WV5JY+ "3S /7%3.T>5P/[/
M4N%X"HR3'$"A12%1*];B=:!378^AD&Y+6W'ZHO_1 KVFABJ&&\TZ:)V8[!:*
M5DO/$R<1<+^?I(\6!J76!KW "NL09DQU]L"H,&HWMDI&8-'7WP[($JNVMM$X
MP(P!>-#I<3WZ\/W@^L/!#/+:X.R;)@I+0:!,T"71]<M+@^EE.\5B#0( ]W%Q
M(A=W//-AT3@@W!%O<"VQZ!8H4X(!@<E!GHG\@,2PJ9*S G\MJ1&700QP.CZ*
M_<%6;EAK$,$JF"6!][%92!<*Z_IY5(DI7J009;,&'[_A*5-2U^_-VI(E-EX4
MH@7H@8AGUZ[7T_5 (E?_#J2Z!MF(/=.=QG1/UJ!(GDXV5%K"@_QCNK3N",KP
MAN80TQ$-- 5,(4&3DJYP1O ']4>4H0 4D3A'IS^HH:4MXE848FF2>_5E&!>O
MA@Y@D4"@Q)*]<Y?J&-$TR?(6B$"PW!6QL:D#@G@RB$MC:E!Y98\&Q&98,!<3
MG/)L?3ZTOJEQZ?O\J[6U'DQJ,N81K$!@T;H"(+G35U(1D5R+_J"8-,D[ROC0
M]V##WX743@BG:_0#T1&N0C&#Y1U%+UM0';\KC$P-"0/E'K>L"',98$4#T7*(
MO_#R<.S7$6&.WZ-[C3,8<@O'#(VEV66H/P0 *&IP;[AF*WQLTAZP+CL0!]<@
MW4,HZORT$<<)V32]:$.R0"3BQM45'0<#I?K?US65B::(5F@Y$J2,(X)>1Y*9
M8FI*#@I*)@$J4YP!B!=0A(P<LEJ![9BB992\I<;4FH[7L$FU[%'A(PW #&(<
MPT_N]F/>'')0M06H(5,QD1FM)<=6,D<N21+_<,G['EYT=R>D V*AZ[:*3;IN
MR_84KH;.6TLJ=^.< O$]DMJ*Q K@0W&ZQ+T>A@VH125"DM(5X6\$=I]EE\Z,
M%=N[*44)%G('$W(D&I]=H9,H8VZRI+9"+11H74&Y=J074*&A9,'-1R(_$+^#
MU0$.$V#IXUS:@1!:EXW* [00 UC&,/'GM2$ 5*N&:IMF>7L_IS/>E XH6:K4
M&G")M7EL6QJ6L+A/E5IU:4*7''E7"-M<_V_?D-"F;=11I0J,(JPHU.^; )JK
MBP6@#&GW8\U(_*.-(0J2H#RA\S/#2^$#$1#5MB055#*UC@+<"X[)%?I<!URX
MB(L4!4N]S\1'H63C& /+L\-J*!I%14U%&2_A?8<BB)-1AJ<R)(SRX#*$C<3A
MI1ERS)#DB"6+FY);ZHXUQS4TH "!-ZGH 3(6%KV'04'<I@@>; "RXK3=5X@E
MM;&$P(T<0P::HV$@#]PU*O"@V6"0&8P* ,!L<>E0R;( @')XGQ /3D%(6MO8
M4$0@*25!)3V';*I\C/X0#ZA>,N::(8!6Y P/42!N$6X VA6-^ C%( GI0:*T
M$=M8;,(#$0 F+7 [!WFF.FF]E"Y* 1QUXTF;RFPH&>@J%^#0&N<@;;EI&9SP
MBBHD:!Y4>$O#-49FYR]9'JIL 4K/IIPO2@:6@0U3#%"8$3)BI.49N&#:16AJ
MXNJ2E1+Y?IIKJ6EB, Y15@R?YB''4[C !2U 4^O'0]P,P1(>:!2!IE">ZPI'
M?Q7CSXCGH[._3^K%RBY, *;4E18(<&X%'MX7":K(HLE([4X@,&WA^1X,I!=,
MIX_D&FJ>C\F>^!W  6(*I*,<6,T)<<F!JDO/0-N]S*2XI/R;Q =6PP;EP&TR
MUH^983PQL!+SX$R-2@S83WR6@J'JA.$( %.2-64K(.'D+;6I*1X/0.  J2PO
M&5K!!MK0&0@KM&Y-&@^XZ"J,\P12;E-&@T!#X$G0Y<Z@CBTM/GHH'G!8V[B"
M:>_/&&4#-/D=#CZ')2*]K*!3(F";?BSQXLJ*'8$U;( YL$:M:$MEWN7F,N '
MI)Q=8U,Z_2'1O[R4DOV*ZA>"( ,Y1GY8EU_G>%\)AU)X?$2^.HB3N!=27B!_
MFLI#$WH_>T-R(H$2,:I@TB#VD9YT_ +PUI&^<:/3>LKHNQ1C4J9E4Q\U2,OO
MUJ130/<;9+8)$I @;*,N,J$ ;17%[J'14]P&!8E"SJ*R9&UZ!SJKV\1JZ]W$
MV23R*R+U86RC+X*[%*(V@@0-@"3G2 LM?6  V>YHS]:@)$?]\3LG^0/U8VK0
M:X<*=WYI^R9-S /9;TR#Q-&U4-)1-3:]:I+\9C(&;P1*C**9A[8J]7>$MJ1(
M4F"$&UH,)NE\>2GV?I&B'73W(K.[)!"9J:JD:2U"U4?OI5'2HL\L)@@B^#84
M&H?"!4/# GQ("C@'J27Q@KB;PCCP:,6,TL#<;JV22;#J(1!?<6"':[,/\($V
M8()84P@JCZ)!HHVRHI9L%)-%+]%3&:.(Z"=A5!P="=1$8@;[<^"8J,1TY]T\
MX/;C+I>7'!GCT7*X[,*K-JZLBZM,8BWEXRH=7@F-CS (5TXJ<@S68HE,X2$\
MIFJ,WZ2[@M838T0&<;/91DB9$^-5A%[-<2(<8WBSDN%MQVN2H@,;2,657-/=
M6AX%!FFCP\0 K#Y:@F"7 /4!F2KPA>C\!B;!6QV-Q20^K8T*[35@F ;,D+Q
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MO!V&__O:?7/UJ1=LO[G]I_GUS?IMN'/XZOOVY:?R2XV2_P]02P$"% ,4
M" "O0,56N9^I;B\#  "]"P  $0              @ $     9&%R92TR,#(S
M,#8P-2YX<V102P$"% ,4    " "O0,56H4WVW?X*  " A@  %0
M    @ %> P  9&%R92TR,#(S,#8P-5]L86(N>&UL4$L! A0#%     @ KT#%
M5E$&/#Y9!P  X5<  !4              ( !CPX  &1A<F4M,C R,S V,#5?
M<')E+GAM;%!+ 0(4 Q0    ( *] Q59K"+9T\RP  /@( 0 *
M  "  1L6  !E>#DY+3$N:'1M4$L! A0#%     @ KT#%5OR#AY9Q+0  PT,!
M  L              ( !-D,  &9O<FTX+6LN:'1M4$L%!@     %  4 -@$
' -!P      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
